TGFB1 and pulmonary arterial hypertension: A study of monocrotaline (MCT)-treated rat model demonstrated that inhibiting the TGF-β pathway with orally active small-molecule transforming growth factor-beta receptor type 1 (TGF-βR1) inhibitor can reduce MCT-induced pulmonary hypertension (MCT-PH) [54].